title: Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine.
abstract: 5-fluorouracil (5-FU), an inhibitor of thymidylate synthase (EC 2.1.1.45), is clinically used in the treatment of several solid tumors, including colorectal, head and neck, gastric, and pancreatic cancer. The drug effectively inhibits deoxynucleoside triphosphate de novo synthesis. However, this inhibition can be circumvented by increased thymidine kinase (EC 2.7.1.21) activity. In the present study we examined the effects of 5-FU combined with azidothymidine (AZT), a competitive inhibitor of thymidine kinase in human colon tumor cells in vitro, including three 5-FU resistant cell lines. The cells were simultaneously incubated with various concentrations of 5-FU (0.015 to 150 microM) and AZT (20 to 300 microM) for 6 days. 5-FU alone yielded an IC50 of 18 microM in the parental CCL 227 cell line and IC50s of 470 and 1100 microM in the 5-FU resistant cell lines as determined by a MTT chemosensitivity assay. Addition of 100 microM AZT alone, a drug concentration that can be achieved in patients, had no effect on the growth of the cell lines examined. However, when added simultaneously with 5-FU, the IC50s of 5-FU synergistically decreased to 10 microM in the sensitive and to 360 or 760 microM in the resistant cell lines, respectively. Our results demonstrate that the combination of 5-FU with AZT synergistically inhibited the growth of 5-FU resistant cells, suggesting the use of 5-FU in combination with AZT for the treatment of 5-FU sensitive as well as resistant human colon tumors.
authors.affiliation: Institute for Medical Chemistry, University of Vienna, School of Medicine, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Findenig
authors.forename: R M
authors.initials: RM
authors.lastname: Mader
authors.forename: M
authors.initials: M
authors.lastname: Fritzer-Szekeres
authors.forename: G G
authors.initials: GG
authors.lastname: Steger
authors.forename: W
authors.initials: W
authors.lastname: Jaeger
authors.forename: T
authors.initials: T
authors.lastname: Szekeres
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000473:pathology*; D004351:Drug Resistance; D004357:Drug Synergism; D005472:Fluorouracil / Q000494:pharmacology*; D006801:Humans; D009962:Orotate Phosphoribosyltransferase / Q000378:metabolism; D013937:Thymidine Kinase / Q000378:metabolism; D013939:Thymidine Phosphorylase / Q000378:metabolism; D013940:Thymidylate Synthase / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014543:Uridine Phosphorylase / Q000378:metabolism; D015215:Zidovudine / Q000494:pharmacology*
chemical_list: D000964:Antimetabolites, Antineoplastic; D015215:Zidovudine; D013940:Thymidylate Synthase; D009962:Orotate Phosphoribosyltransferase; D014543:Uridine Phosphorylase; D013939:Thymidine Phosphorylase; D013937:Thymidine Kinase; D005472:Fluorouracil